Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Study Overview: Eli Lilly and Company is conducting a Phase 1 study titled ‘A Phase 1, Open-label, 2-part Study of the Absorption, Metabolism, Excretion, and Bioavailability of [14C]-LY4065967 in Healthy Male Participants.’ The study aims to understand how LY4065967 is absorbed, metabolized, and excreted in the body, which is crucial for assessing its potential as a therapeutic agent.
Intervention/Treatment: The study involves two parts: Part 1 tests a single oral dose of [14C]-LY4065967, while Part 2 involves an oral dose of LY4065967 followed by an intravenous dose of [14C]-LY4065967. These interventions aim to provide comprehensive data on the drug’s bioavailability and metabolism.
Study Design: This is an interventional study with a non-randomized, parallel assignment model. There is no masking involved, and the primary purpose is basic science, focusing on understanding the drug’s pharmacokinetics in healthy participants.
Study Timeline: The study began on June 23, 2025, with the last update posted on July 16, 2025. These dates are important as they indicate the study’s current recruiting status and progress.
Market Implications: This study could influence Eli Lilly’s stock performance by providing insights into a new drug’s potential, affecting investor sentiment. As the study progresses, positive results could enhance Eli Lilly’s competitive position in the pharmaceutical industry.
The study is currently ongoing, with further details available on the ClinicalTrials portal.